Read on Twitter
Dear $PFE : Show us the data. https://twitter.com/FrancoiseBaylis/status/1325769880994504707
As reported in @statnews by @matthewherper, to its credit $PFE dropped the idea of running an interim analysis at the 32-case mark, waiting instead until 94 cases appeared in its sample. https://www.statnews.com/2020/11/09/covid-19-vaccine-from-pfizer-and-biontech-is-strongly-effective-early-data-from-large-trial-indicate/
But as many have already said, it's critical to complete the trial (164 cases) + that may be more challenging to do if/when $PFE files for an Emergency Use Authorization from the USFDA (likely by late November).
In the meantime, tho, if $PFE wants to enhance trust in these promising findings, the best strategy is to make its findings open to independent scrutiny.
$PFE was one of the first companies to make its phase 3 trial protocol public.... https://www.nytimes.com/2020/09/17/health/covid-moderna-vaccine.html
$PFE was one of the first companies to make its phase 3 trial protocol public.... https://www.nytimes.com/2020/09/17/health/covid-moderna-vaccine.html
That's how we knew they had (originally) planned to run an interim analysis after only 32 cases.
Now it's time to follow through by making the data, and the interpretation of the data by the Data Safety Monitoring Board (DSMB) available for independent review.
Now it's time to follow through by making the data, and the interpretation of the data by the Data Safety Monitoring Board (DSMB) available for independent review.
Were the trial happening in Canada, we'd argue that is what @GovCanHealth can + should make $PFE do.
https://osf.io/evhnk/
Hopefully $PFE will do that on its own initiative and/or @US_FDA will nudge them in that direction.
https://osf.io/evhnk/
Hopefully $PFE will do that on its own initiative and/or @US_FDA will nudge them in that direction.